Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer

Methods: Female patients with a diagnosis of ILC or IDC in The Netherlands between July 2008 and December 2012 were identified through the population-based Netherlands Cancer Registry.

Results: A total of 466 ILC patients received NAC compared with 3622 IDC patients. Downstaging by NAC was seen in 49.7 % of the patients with ILC and in 69.6 % of the patients with IDC, and a pathologic complete response (pCR) was observed in 4.9 and 20.2 % of these patients, respectively (P < 0.0001). Breast-conserving surgery was performed for 24.4 % of the patients with ILC receiving NAC versus 39.4 % of the patients with IDC. In the ILC group, 8.2 % of the patients needed surgical reinterventions after BCS due to tumor-positive resection margins compared with 3.4 % of the patients with IDC (P < 0.0001). Lobular histology was independently associated with a higher mastectomy rate (odds ratio 1.91; 95 % confidence interval 1.49-2.44). Among the patients with clinical T2 and T3 disease, BCS was achieved more often when NAC was administered in ILC as well as IDC.

Conclusion: The patients with ILC receiving NAC were less likely to experience a pCR and less likely to undergo BCS than the patients with IDC. With regard to BCS, the impact of NAC for ILC patients was lower than for patients receiving surgery without NAC. However, despite the high number to treating in order to achieve BCS, a small subset of ILC patients, especially cT2 and cT3 patients, still may benefit from NAC.

Citing Articles

The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patient Receiving Neoadjuvant Chemotherapy.

Szwiec M, Tomiczek-Szwiec J, Marciniak W, Derkacz R, Huzarski T, Cybulski C Cancers (Basel). 2025; 17(5).

PMID: 40075686 PMC: 11898521. DOI: 10.3390/cancers17050839.

Mutations Matter: Unravelling the Genetic Blueprint of Invasive Lobular Carcinoma for Progression Insights and Treatment Strategies.

Kontogiannis A, Karaviti E, Karaviti D, Lanitis S, Gomatou G, Syrigos N Cancers (Basel). 2024; 16(22).

PMID: 39594781 PMC: 11593237. DOI: 10.3390/cancers16223826.

Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.

Dayan D, Lukac S, Rack B, Ebner F, Fink V, Leinert E Breast Cancer Res. 2023; 25(1):153.

PMID: 38098086 PMC: 10722735. DOI: 10.1186/s13058-023-01750-0.

Metastatic Leptomeningeal Carcinomatosis From Primary Lobular Breast Cancer Found in a Medical School Cadaveric Dissection.

Mitchell M, Pollock 3rd J, Downs M, Stephen D Cureus. 2023; 15(9):e44533.

PMID: 37790014 PMC: 10544739. DOI: 10.7759/cureus.44533.

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.

Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M Ann Surg Oncol. 2023; 30(12):7099-7106.

PMID: 37561345 PMC: 10562340. DOI: 10.1245/s10434-023-14075-1.

References

Pestalozzi B, Zahrieh D, Mallon E, Gusterson B, Price K, Gelber R . Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008; 26(18):3006-14. DOI: 10.1200/JCO.2007.14.9336. View

Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T . Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996; 77(1):113-20. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8. View

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S, Broglio K, Theriault R . Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2004; 23(1):41-8. DOI: 10.1200/JCO.2005.03.111. View

Li C, Uribe D, Daling J . Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005; 93(9):1046-52. PMC: 2361680. DOI: 10.1038/sj.bjc.6602787. View

Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere J, Bouita L, Cohen-Solal C . Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006; 17(8):1228-33. DOI: 10.1093/annonc/mdl114. View

Katz A, Saad E, Porter P, Pusztai L . Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007; 8(1):55-62. DOI: 10.1016/S1470-2045(06)71011-7. View

van den Broek N, van der Sangen M, van de Poll-Franse L, van Beek M, Nieuwenhuijzen G, Voogd A . Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer. Breast Cancer Res Treat. 2006; 105(1):63-8. DOI: 10.1007/s10549-006-9431-5. View

Waljee J, Hu E, Newman L, Alderman A . Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008; 15(5):1297-303. DOI: 10.1245/s10434-007-9777-x. View

Soucy G, Belanger J, Leblanc G, Sideris L, Drolet P, Mitchell A . Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?. J Am Coll Surg. 2008; 206(6):1116-21. DOI: 10.1016/j.jamcollsurg.2007.12.025. View

10.

Boughey J, Wagner J, Garrett B, Harker L, Middleton L, Babiera G . Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009; 16(6):1606-11. PMC: 4338983. DOI: 10.1245/s10434-009-0402-z. View

11.

Straver M, Rutgers E, Rodenhuis S, Linn S, Loo C, Wesseling J . The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010; 17(9):2411-8. PMC: 2924493. DOI: 10.1245/s10434-010-1008-1. View

12.

Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P . Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. Ann Surg Oncol. 2011; 19(2):519-26. DOI: 10.1245/s10434-011-1879-9. View

13.

Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L . Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol. 2011; 19(4):1107-14. DOI: 10.1245/s10434-011-1907-9. View

14.

Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas C . Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer. 2013; 108(2):285-91. PMC: 3566807. DOI: 10.1038/bjc.2012.557. View

15.

Vriens B, Aarts M, de Vries B, van Gastel S, Wals J, Smilde T . Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer. 2013; 49(15):3102-10. DOI: 10.1016/j.ejca.2013.06.012. View

16.

Petrelli F, Barni S . Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res Treat. 2013; 142(2):227-35. DOI: 10.1007/s10549-013-2751-3. View

17.

Loibl S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H . Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014; 144(1):153-62. DOI: 10.1007/s10549-014-2861-6. View

18.

Truin W, Roumen R, Siesling S, van der Heiden-van der Loo M, Duijm L, Tjan-Heijnen V . Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands. Ann Surg Oncol. 2014; 22(5):1471-8. DOI: 10.1245/s10434-014-4175-7. View

19.

Cocquyt V, Blondeel P, Depypere H, Praet M, Schelfhout V, Silva O . Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003; 29(4):361-7. DOI: 10.1053/ejso.2002.1404. View

20.

Mathieu M, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli J . The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004; 40(3):342-51. DOI: 10.1016/j.ejca.2003.08.015. View